Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mario Cazzola and Paola Rogliani.
Mario Cazzola
Connection Strength
15.853
Paola Rogliani
  1. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
    View in: PubMed
    Score: 0.840
  2. Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ Evid Based Med. 2018 10; 23(5):183-184.
    View in: PubMed
    Score: 0.774
  3. Is ICS-LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018 05; 6(5):316-317.
    View in: PubMed
    Score: 0.762
  4. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.759
  5. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin Drug Saf. 2018 Apr; 17(4):429-435.
    View in: PubMed
    Score: 0.758
  6. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulm Pharmacol Ther. 2018 04; 49:20-26.
    View in: PubMed
    Score: 0.748
  7. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J Comp Eff Res. 2017 Oct; 6(7):627-636.
    View in: PubMed
    Score: 0.730
  8. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. Evid Based Med. 2017 10; 22(5):183-184.
    View in: PubMed
    Score: 0.729
  9. Adherence to COPD treatment: Myth and reality. Respir Med. 2017 08; 129:117-123.
    View in: PubMed
    Score: 0.720
  10. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017 03; 124:6-14.
    View in: PubMed
    Score: 0.702
  11. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J. 2011 Sep; 20(3):291-8.
    View in: PubMed
    Score: 0.483
  12. Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung. 2021 08; 199(4):335-343.
    View in: PubMed
    Score: 0.241
  13. Controversy surrounding the Sputnik V vaccine. Respir Med. 2021 10; 187:106569.
    View in: PubMed
    Score: 0.240
  14. Management of COPD patients during COVID: difficulties and experiences. Expert Rev Respir Med. 2021 08; 15(8):1025-1033.
    View in: PubMed
    Score: 0.237
  15. Disputes over the production and dissemination of misinformation in the time of COVID-19. Respir Med. 2021 06; 182:106380.
    View in: PubMed
    Score: 0.234
  16. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines (Basel). 2021 Mar 05; 9(3).
    View in: PubMed
    Score: 0.233
  17. Guidance on nebulization during the current COVID-19 pandemic. Respir Med. 2021 01; 176:106236.
    View in: PubMed
    Score: 0.229
  18. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respir Med. 2020 09; 171:106114.
    View in: PubMed
    Score: 0.224
  19. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Oct; 28(10):827-833.
    View in: PubMed
    Score: 0.210
  20. Pharmacological treatment and current controversies in COPD. F1000Res. 2019; 8.
    View in: PubMed
    Score: 0.210
  21. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019 07; 40(7):452-463.
    View in: PubMed
    Score: 0.206
  22. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019 05; 151:43-48.
    View in: PubMed
    Score: 0.204
  23. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019 04; 20(6):737-750.
    View in: PubMed
    Score: 0.202
  24. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0.200
  25. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother. 2018 Dec; 19(18):2043-2053.
    View in: PubMed
    Score: 0.198
  26. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct; 14(10):1101-1111.
    View in: PubMed
    Score: 0.197
  27. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018; 13:3115-3130.
    View in: PubMed
    Score: 0.197
  28. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 08; 12(8):693-708.
    View in: PubMed
    Score: 0.194
  29. Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? Expert Opin Investig Drugs. 2018 07; 27(7):573-581.
    View in: PubMed
    Score: 0.194
  30. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018 06; 17(6):589-596.
    View in: PubMed
    Score: 0.192
  31. Impact of doxofylline in COPD: A pairwise meta-analysis. Pulm Pharmacol Ther. 2018 08; 51:1-9.
    View in: PubMed
    Score: 0.191
  32. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018 04 12; 19(1):65.
    View in: PubMed
    Score: 0.191
  33. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018 06; 50:28-37.
    View in: PubMed
    Score: 0.190
  34. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018 05; 17(5):509-517.
    View in: PubMed
    Score: 0.190
  35. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018 04; 12(4):261-264.
    View in: PubMed
    Score: 0.189
  36. Long-term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. Pol Arch Intern Med. 2018 01 31; 128(1):4-6.
    View in: PubMed
    Score: 0.188
  37. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2):239-245.
    View in: PubMed
    Score: 0.187
  38. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018 02; 48:185-194.
    View in: PubMed
    Score: 0.186
  39. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018 01; 12(1):43-54.
    View in: PubMed
    Score: 0.185
  40. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends Pharmacol Sci. 2017 10; 38(10):940-951.
    View in: PubMed
    Score: 0.182
  41. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.182
  42. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respir Med. 2017 08; 129:189-198.
    View in: PubMed
    Score: 0.181
  43. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Ther. 2017 08; 45:148-158.
    View in: PubMed
    Score: 0.180
  44. An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017 Jul; 18(10):973-988.
    View in: PubMed
    Score: 0.179
  45. Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther. 2017 Dec; 47:88-92.
    View in: PubMed
    Score: 0.179
  46. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May; 77(7):721-732.
    View in: PubMed
    Score: 0.179
  47. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017 03; 11(3):239-253.
    View in: PubMed
    Score: 0.176
  48. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017 01 24; 18(1):26.
    View in: PubMed
    Score: 0.175
  49. Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf. 2017 Jan; 8(1):17-30.
    View in: PubMed
    Score: 0.171
  50. Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opin Emerg Drugs. 2018 09; 23(3):185-199.
    View in: PubMed
    Score: 0.049
  51. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. Eur J Pharmacol. 2018 Aug 05; 832:114-119.
    View in: PubMed
    Score: 0.048
  52. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018 Jul; 103:1-8.
    View in: PubMed
    Score: 0.048
  53. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017; 12:2687-2693.
    View in: PubMed
    Score: 0.046
  54. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD. 2017 Oct; 14(5):526-532.
    View in: PubMed
    Score: 0.045
  55. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Oct 05; 812:147-154.
    View in: PubMed
    Score: 0.045
  56. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan; 26(143).
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.